Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

Epidemiology and Infection

Volumn 133, Issue 4, 2005, Pages 687-693

  Iob, A ^a   Brianti, G ^a   Zamparo, E ^a   Gallo, T ^a  

^a Azienda Servizi Sanitari No 3 ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIPPAL S1; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; M59 ADJUVANT VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HEALTH CARE FACILITY; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT;

ADJUVANTS, IMMUNOLOGIC; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HOMES FOR THE AGED; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; INFLUENZA VACCINES; INFLUENZA, HUMAN; ITALY; LONG-TERM CARE; MALE; NURSING HOMES; ODDS RATIO; POLYSORBATES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SQUALENE;

EID: 22544452446     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268805003936     Document Type: Article

References (30)

1. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362: 1733-1745.
2. Nichol KL. The efficacy, effectiveness and cost effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21: 1769-1775.
3. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1999; 48: 1-28.
4. Fiebach N, Beckett W. Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines. Arch Intern Med 1994; 154: 2545-2557.
5. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York: Alan R. Liss, Inc., 1986: 155-168.
6. Barker WH, Mullooly JP. Effectiveness of inactivated influenza vaccine among non-institutionalised elderly persons. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York: Alan R. Liss, Inc., 1986: 169-182.
7. Govaert TNI, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. J Am Med Assoc 1994; 272: 1661-1665.
8. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons, A meta-analsyis and review of the literature. Ann Intern Med 1995; 123: 518-527.
9. Gross PA, Quinnan Jr. GV, Weksler ME, Setia U, Douglas Jr. RG. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine 1989; 7: 303-308.
10. Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE, Habel LA. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38-44.
11. O'Hagan DT, Ott GS, Van Nest G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 1997; 3: 69-75.
12. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19: 2673-2680.
13. Minutello M, Senatore F, Cecchinelli G, et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17: 99-104.
14. De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17: 3094-3101.
15. Banzhoff A, Nacci P, Podda A. A new MF-59 adjuvanted vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49: 177-184.
16. Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001; 154: 155-160.
17. ISTAT (Italian Census Bureau). 2001 Census (http://dawinci.istat.it).
18. Couch RB, Kasel JA. Immunity to influenza in man. Ann Rev Microbiol 1983; 37: 529-549.
19. Fries LF, Dillon SB, Hildreth JE, et al. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. J Infect Dis 1993; 167: 593-601.
20. Pyhala R, Aho K. Serum HI antibody and protection against influenza: a follow-up survey at community level of three epidemics caused by different H3N2 variants. Int J Epidemiol 1975; 4: 127-129.
21. Rytel MW, Jackson LJ, Ferstenfeld JE, Rosenkranz MA. New live attenuated influenza A/England/42/72 (H3N2) vaccine (Alice): reactogenicity, immunogenicity, and protection efficacy. J Infect Dis 1975; 132: 652-659.
22. Hirota Y, Kaji M, Ide S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997; 15: 962-967.
23. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp 120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001; 183: 1343-1352.
24. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35: 69-75.
25. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96:12 March 1997.
26. Puig Barberà J, Diez-Domingo J, Pérez-Hoyos SS, Belenguer-Varea A, González-Vidal D. Effectiveness of an influenza vaccine adjuvanted with MF59 in non-institutionalised persons over 64 years of age: a phase IV case-control study [in Spanish] [oral presentation no. 54]. 2nd National Congress, Spanish Association of Vaccinology, 13-15 Nov. 2003, Las Palmas, Grand Canary Island.
27. Carroll RJ, Pederson S. On robustness in the logistic regression model. J Roy Statist Soc, Series B, Methodological 1993; 55: 693-706.
28. Prugliasco F, Mensi C, Giussani F, Anselmi G. Italian influenza surveillance network: results of the first year of activity. The Collaborative Group for influenza surveillance. Eur J Epidemiol 1999; 15: 301-302.
29. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J Am Med Assoc 2003; 289: 179-186.
30. Prevention and Control of Influenza. Recommendations for the 2003-2004 season (http://www.ministerosalute.it/resources/static/primopiano/176/ Circolare_influenza_2003-2004.doc). Accessed 1 March 2004.